Application of gene therapy in the treatment of superficial digital flexor tendon injury in horses

Open Vet J. 2020 Oct;10(3):261-266. doi: 10.4314/ovj.v10i3.3. Epub 2020 Jul 31.

Abstract

Background: Tendon injuries are one of the most common causes of orthopedic disorders in horses. Such injuries involve a long course of treatment and recovery. The most promising method of treating these injuries is the use of recombinant proteins and gene therapy.

Aim: In this work, we evaluated the therapeutic efficacy of plasmid DNA (pDNA) containing two species-specific coding sequences, i.e. vascular endothelial growth factor 164 (VEGF164) and fibroblast growth factor 2 (FGF2), in the treatment of severe damage to the tendon of the superficial digital flexor.

Methods: A pDNA construct was used to restore the damaged superficial digital flexor tendon in the horse.

Results: This study showed that the administration of pDNA encoding VEGF164 and FGF2 genes at the injury area increased the regenerative activities of the damaged tendon.

Conclusion: This study shows the therapeutic properties of genetic constructs (pDNA) and contributes to the advancements in the use of these therapies.

Keywords: Fibroblast growth factor 2; Plasmid DNA; Superficial digital flexor; Vascular endothelial growth factor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Fibroblast Growth Factor 2 / therapeutic use*
  • Genetic Therapy / statistics & numerical data
  • Genetic Therapy / veterinary*
  • Horses / injuries*
  • Male
  • Plasmids / therapeutic use*
  • Tendon Injuries / therapy
  • Tendon Injuries / veterinary*
  • Vascular Endothelial Growth Factor A / therapeutic use*

Substances

  • Vascular Endothelial Growth Factor A
  • Fibroblast Growth Factor 2